NCT01019421已完成2 期
Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Lu AE58054 in Patients With Moderate Alzheimer's Disease Treated With Donepezil
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 278
- 试验地点
- 51
- 主要终点
- Change in cognition after 24 weeks
研究概览
简要总结
The purpose of this study is to accept or reject the hypothesis that Lu AE58054 improves cognition and functional outcomes in patients with moderate Alzheimer's Disease, already in treatment with donepezil.
详细描述
Multi-centre, randomised, double-blind, parallel-group, placebo-controlled, fixed-dose study of Lu AE58054 as add-on to donepezil. The patient has probable Alzheimer's Disease consistent with the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient (or if applicable the legally acceptable representative (LAR) and if different from the responsible caregiver) and the responsible caregiver are able to read and understand the Informed Consent Form.
- •The patient has a knowledgeable and reliable caregiver who will accompany the patient to all clinic visits during the study.
- •The patient (or if applicable the LAR and if different from the responsible caregiver) and the responsible caregiver have signed the Informed Consent Form.
- •The patient has probable AD consistent with NINCDS-ADRDA criteria.
- •The patient is a man or woman, aged at least 50 years.
- •The patient has been treated with donepezil on a stable dose for at least 3 months prior to screening.
排除标准
- •The patient has evidence of any clinically significant neurodegenerative disease or other serious neurological disorders other than AD including but not limited to Lewy body dementia, fronto-temporal dementia, Parkinson's disease, Huntington's disease, major cortical stroke, major head trauma and, primary or secondary cerebral neoplasia.
- •The patient has a Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR) Axis I disorder other than AD including amnestic disorders, major depressive disorder, delirium, schizophrenia or schizoaffective disorder, bipolar disorder, psychosis, panic, post traumatic stress disorder or/and cognitive disorder not otherwise specified.
- •The patient has clinical and radiological findings that fulfil the standards of the National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherché et l'Enseignement en Neurosciences (NINDS-AIREN) criteria for vascular dementia.
- •The patient has CT or MRI evidence of hydrocephalus, stroke, a space-occupying lesion, cerebral infection or any clinically significant central nervous system disease other than AD.
- •The patient has clinically significant abnormal vital signs.
- •The patient has one or more laboratory values outside the normal range, based on the blood or urine samples, which are, in the investigator's judgement, considered to be clinically significant.
- •The patient has a clinically significant abnormal ECG.
- •The patient has an oncological diagnosis (haematological or solid tumour) that is currently being treated, or for which there has been treatment within 5 years preceding screening, or for which there is still evidence of active disease (patients with local dermatological tumours such as basal or squamous cell carcinoma may be included).
- •The patient's donepezil therapy is likely to be interrupted or discontinued during the study.
- •The patient has a disease or takes medication that, in the investigator's judgement, could interfere with the assessments of safety, tolerability, or efficacy.
- •The patient is, in the investigator's judgement, unlikely to comply with the clinical study protocol or is unsuitable for any reason.
- •The patient is a member of the site personnel or their immediate families.
- •The patient is treated against his/her will (for example, by court order).
- •The patient or patient caregiver is unwilling or unable to abide by the visit schedule and other requirements of the study.
研究组 & 干预措施
Lu AE58054
Experimental
干预措施: Lu AE58054 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Change in cognition after 24 weeks
时间窗: Week 24
次要结局
- Change in global function, activities of daily living, safety and tolerability, pharmacokinetics/pharmacodynamics(Week 24)
研究者
研究点 (51)
Loading locations...
相似试验
已完成
2 期
Efficacy Study Exploring the Effect of Lu AE58054 as Augmentation Therapy in Patients With SchizophreniaCognitionSchizophreniaNCT00810667H. Lundbeck A/S124
已完成
2 期
Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive DisorderDepressive Disorder, MajorNCT01564862Takeda602
已完成
早期 1 期
The Effect of Cognitive Function as Measured by Repeated Cognitive Measures After 12 Weeks Treatment With DonepezilAlzheimer's DiseaseNCT01024660AstraZeneca155
尚未招募
Unknown
FMT for CDAD decolonizatioKCT0008752Inha University Hospital20
已完成
1 期
Study of Lemborexant-Alcohol Interaction in Healthy SubjectsHealthy SubjectsNCT03483636Eisai Inc.24